Unlike 1-day VRBPAC-to-EUA timeline of peers, Novavax’s Covid-19 jab awaits FDA review of recent manufacturing data
Moderna, Pfizer/BioNTech and Johnson & Johnson all received FDA clearance for their Covid-19 vaccines a day after the agency’s advisors recommended emergency authorization. The same will not happen for Novavax.
The regulator’s outside experts recommended 21 to 0 on Tuesday afternoon to give an emergency green light to the Maryland biotech’s vaccine, but more than 36 hours later, an official OK hasn’t been handed down yet. The FDA received manufacturing updates from the company just days before the advisory committee’s hours-long hearing.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.